NK 010
Alternative Names: NK-010Latest Information Update: 11 Nov 2024
Price :
$50 *
At a glance
- Originator NK CellTech
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Ovarian cancer; Solid tumours
Most Recent Events
- 06 Nov 2024 Guangdong Provincial People's Hospital plans a phase I trial for Systemic lupus erythematosus (Combination therapy) in China (IV) (NCT06676631)
- 22 Jan 2024 Preclinical trials in Acute myeloid leukaemia in China (Parenteral) prior to January 2024
- 22 Jan 2024 Preclinical trials in Ovarian cancer in China (Parenteral) prior to January 2024